Table 4.
Differences in the sensitivity of serum GL and MG-H1 levels to existing drug treatments
| T2D |
With n, (%) | GL |
MG-H1 |
GL |
MG-H1 |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oral administration | OR | 95% CI (Lower/Upper) | p | OR | 95% CI (Lower/Upper) | p | OR | 95% CI (Lower/Upper) | p | OR | 95% CI (Lower/Upper) | p | |
| Glucose-independent insulin secretagogue | 49 (32) | 1.178 | 0.546/2.556 | 0.676 | 1.105 | 0.495/2.504 | 0.809 | ||||||
| Sulfonylurea | 31 (20) | 1.146 | 0.453/2.924 | 0.774 | 0.864 | 0.317/2.374 | 0.774 | ||||||
| Glinide | 18 (12) | 1.323 | 0.459/3.940 | 0.605 | 1.791 | 0.571/6.084 | 0.329 | ||||||
| Glucose-dependent insulin secretagogue | 127 (83) | 1.296 | 0.512/3.327 | 0.584 | 3.439 | 1.263/10.040 | 0.019∗ | ||||||
| DPP-4 inhibitor | 100 (65) | 1.253 | 0.489/3.245 | 0.638 | 2.465 | 0.938/6.764 | 0.072 | ||||||
| GLP-1 receptor agonist | 27 (18) | 1.097 | 0.342/3.544 | 0.876 | 6.703 | 1.908/25.590 | 0.004∗∗ | ||||||
| Carbohydrate absorption/excretion regulator | 95 (62) | 1.020 | 0.515/2.020 | 0.954 | 1.420 | 0.688/2.981 | 0.347 | ||||||
| α-Glucosidase inhibitor | 23 (15) | 0.849 | 0.334/2.133 | 0.726 | 1.777 | 0.670/4.942 | 0.255 | ||||||
| SGLT2 inhibitor | 83 (54) | 1.137 | 0.593/2.186 | 0.698 | 1.353 | 0.680/2.718 | 0.391 | ||||||
| Insulin sensitizer | 78 (51) | 0.916 | 0.443/1.887 | 0.811 | 0.462 | 0.210/0.989 | 0.049∗ | ||||||
| Biguanide | 72 (47) | 0.911 | 0.426/1.940 | 0.808 | 0.269 | 0.112/0.610 | 0.002∗∗ | ||||||
| Thiazolidine | 18 (12) | 0.709 | 0.246/1.978 | 0.511 | 1.440 | 0.493/4.285 | 0.504 | ||||||
| Insulin | 25 (16) | 1.708 | 0.694/4.364 | 0.250 | 2.749 | 1.016/8.081 | 0.053 | ||||||
| Statin | 104 (68) | 1.142 | 0.555/2.365 | 0.718 | 0.354 | 0.159/0.761 | 0.009∗∗ | ||||||
| Antihypertensive drug | 89 (58) | 1.593 | 0.828/3.093 | 0.165 | 1.446 | 0.722/2.913 | 0.299 | ||||||
| RAS inhibitor | 65 (43) | ||||||||||||
| Calcium channel blocker | 66 (43) | ||||||||||||
The objective variable was discrete: 0 for groups of GL or MG-H1 levels below the median and one for groups above the median. The explanatory variable was discrete: 0 for patients without and one for patients with therapeutic drug. n, the number of patients with type 2 diabetes, who receive treatment with the therapeutic drug.
CI, confidence interval; DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; OR, odds ratio; RAS, renin-angiotensin system; SGLT2, sodium glucose cotransporter-2; T2D, type 2 diabetes.
∗p < 0.05; ∗∗p < 0.01.